In the third quarter, Commerzbank Aktiengesellschaft FI reduced its stake in AbbVie by 30.5%, selling 39,586 shares and ending the period with 90,102 shares valued at $20.86 million. Meanwhile, Norges Bank initiated a new position worth approximately $4.29 billion, and Laurel Wealth Advisors LLC expanded its holding by 18,384.4%, acquiring 5,675,095 shares for $1.06 billion. Vanguard Group added 3.38 million shares to bring its total to 177.30 million shares ($32.91 billion), DZ BANK AG raised its stake by 169.3% to 4.72 million shares ($876.66 million), and Raymond James Financial increased its holding by 41.8% to 9.34 million shares ($1.73 billion). Overall, institutional and hedge fund ownership stands at 70.23%.

On October 31, AbbVie reported third-quarter EPS of $1.86, surpassing the consensus estimate of $1.77 by $0.09. Revenue grew 9.1% year-over-year to $15.78 billion, above the $15.58 billion analysts expected. Net margin remained at 4.0%, and return on equity reached an exceptional 3,216.47%. Management issued full-year guidance of $3.32–$3.36 in EPS for Q4, supporting an average analyst forecast of $12.31 for the fiscal year.

AbbVie declared a quarterly dividend of $1.73 per share, up from $1.64, representing an annualized payout of $6.92 and a yield of approximately 3.2%. The ex-dividend date was January 16, with payment scheduled for February 17. With a dividend payout ratio of 524.24%, the company maintains its status among Dividend Kings. Consensus among 23 analysts is a Moderate Buy rating, reflecting stable long-term income potential and attractive expected returns.